Cancer treatments Press Release
|06/22/2020 - 14:16||
Study led by City of Hope, TGen shows new way of identifying tumor response to immunotherapy
DUARTE, Calif. — Scientists at City of Hope, working in collaboration with researchers at Translational Genomics Research Institute (TGen) and other colleagues across the country, have found that the actions of circulating immune cells — namely how they differentiate and signal — at the start of immunotherapy treatment for cancer can inform how a patient will respond to the therapy. The team’s findings will publish this week in the Proceedings of the National Academy of Sciences of the United States of America.
|City of Hope Na...|
|06/22/2020 - 12:24||
DelMar Pharmaceuticals Presents Positive Interim Data on VAL-083 Demonstrating Favorable Outcomes in Both Newly- Diagnosed and Recurrent GBM at the AACR Virtual Annual Meeting II
DelMar previously announced its invitation from GCAR to participate in the selective GBM AGILE study. This pivotal study, with its robust trial design, industry leading partners, and strong regulatory endorsement, is intended to serve as the basis for VAL-083's new drug application (NDA) submission and registration.
|06/15/2020 - 05:22||
Bellicum Receives FDA IND Clearance to Initiate a Phase 1/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T for HER2+ Solid Tumors
BPX-603 is a GoCAR-T ® product candidate targeting solid tumors that express human epidermal growth factor receptor 2 (HER2). BPX-603 is the company’s first dual-switch GoCAR-T ® product candidate, which incorporates both the company’s iMC activation and CaspaCIDe ® safety switch technologies.
|06/13/2020 - 07:04||
Halozyme Announces Findings From Janssen's Phase 3 Andromeda Study Evaluating Subcutaneous Daratumumab Utilizing ENHANZE In Light-Chain Amyloidosis Presented At European Hematology Association 25th Annual Congress
Janssen reported that the study met the primary endpoint of percentage of patients with hematologic complete response. Additional information can be accessed here .
|06/11/2020 - 17:11||
Two new, powerful small molecules may be able to kill cancers that other therapies cant
DUARTE, Calif. — City of Hope scientists have identified and developed two potent small molecules that appear to suppress tumor growth in multiple cancers even when other treatments cease to work, possibly due to the development of drug resistance.
|City of Hope Na...|
|06/11/2020 - 04:11||
City of Hope signs licensing agreement with Scopus BioPharma Inc. to develop novel, targeted immuno-oncology gene therapy
DUARTE, Calif. — City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, has signed an exclusive, worldwide licensing agreement with Scopus BioPharma Inc., a biopharmaceutical company focused on novel therapeutics for serious diseases with significant unmet medical needs. Scopus will further develop and plans to commercialize a City of Hope first-in-class, targeted immuno-oncology gene therapy.
|City of Hope Na...|
|06/11/2020 - 03:10||
BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1 Synthesized by AMRI
Under the first agreement, Neurotrope will transfer to BryoLogyx the right to develop bryostatin‑1 for the potential treatment of CD22+ B-cell acute lymphoblastic leukemia (ALL). Relapsed ALL in CD22 CAR-T treated patients has been associated with reduced CD22 antigen density. Bryostatin-1 has been shown to increase CD22 expression levels in leukemia patients, and in a mouse model, resulted in improved treatment response and durability. Neurotrope will also transfer to BryoLogyx the Investigational New Drug (“IND”) application that is in development.
|06/09/2020 - 09:07||
OncoSec Expands KEYNOTE-890 Trial into First-Line Metastatic Triple Negative Breast Cancer (mTNBC) with TAVO and KEYTRUDA Plus Chemotherapy
|06/04/2020 - 05:49||
OncoSec to Present at Virtual Summer Investor Summit
PENNINGTON, N.J. and SAN DIEGO, June 4, 2020 / / -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, President and Chief Executive Officer of OncoSec, will present a company overview at the Virtual Summer Investor Summit on Tuesday, June 9 th at 9:45 a.m.
|06/03/2020 - 04:49||
CAR T Cell Therapy Market Global Forecast by Regions & Targeted Antigens
According to Renub Research analysis CAR-T Cell Therapy Market is expected to be USD 7.4 Billion by 2028. Global Forecast by Regions, Targeted Antigens, Clinical Trials/Study, Companies.
|05/31/2020 - 19:38||
CELLULAR IMMUNOTHERAPY ADVANCES AT ASCO20
CAR T cell therapy targeting the CD19 marker has already made an impact in B cell blood cancers, particularly leukemia and lymphoma . As noted by Suzanne Lentzsch, Ph.D. , a CRI CLIP Investigator at Columbia University Medical Center, there was a 45 percent decrease in stem cell transplants among lymphoma patients with diffuse large B cell lymphoma in 2018 compared to 2017, which she suggested was likely due to the FDA approval of the first CAR T cell immunotherapy for lymphoma in 2017.
|05/29/2020 - 14:03||
Less Intense Treatment Safe for HPV+ Throat Cancer
PITTSBURGH – A less intense treatment for human papillomavirus positive (HPV+) throat cancer—using robotic surgery followed by low-dose radiation—could provide as much benefit as standard higher-dose radiation and chemotherapy while preserving a patient’s throat function, and with potentially less toxicities, according to researchers at UPMC Hillman Cancer Center and Yale Cancer Center .
|05/29/2020 - 10:59||
Imfinzi showed a sustained overall survival benefit in 1st-line extensive-stage small cell lung cancer in the Phase III CASPIAN trial
The safety and tolerability for Imfinzi plus chemotherapy was consistent with the known safety profile of these medicines. Results showed 62.3% of patients experienced a Grade 3 or 4 adverse event with Imfinzi plus chemotherapy (all causes) versus 62.8% with chemotherapy alone. The percentage of patients discontinuing treatment (all causes) was 10.2% for Imfinzi plus chemotherapy and 9.4% for chemotherapy alone.
|05/29/2020 - 10:22||
Imfinzi plus tremelimumab demonstrated promising clinical activity and tolerability in patients with advanced liver cancer
Results evaluating safety and efficacy from parts two and three of the Phase II Study 22 trial were presented during the 2020 American Society of Clinical Oncology ASCO20 Virtual Scientific Program on Friday, 29 May 2020.
|05/27/2020 - 00:46||
Bellicum to Participate in Two Upcoming Virtual Investor Conferences
Live webcasts of the fireside chat and presentation may be accessed from the Events & Presentation section of the Bellicum website. An archived version of each webcast will be available for replay immediately following the event.
|05/22/2020 - 00:14||
Enhertu granted Orphan Drug Designation in the US for gastric cancer
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) has been granted Orphan Drug Designation (ODD) in the US for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.
|05/21/2020 - 15:55||
How Immunotherapy Is Transforming Bladder Cancer Treatment
Bladder cancer affects an estimated 550,000 people worldwide each year, including 80,000 in the U.S. Most cases of bladder cancer are caught early and are treatable with a bacteria-based immunotherapy called Bacillus Calmette-Guérin, or BCG, as well as traditional treatments like surgery and chemotherapy.
|05/18/2020 - 11:50||
Seattle Genetics Antibody-Drug Conjugate Innovation and Targeted Therapy Programs to be Featured at the AACR Virtual Annual Meeting II on June 22-24, 2020
Building on our expertise in CD30 targeted therapies, data will be presented from a new CD30-directed ADC that employs our novel camptothecin ADC technology and is being investigated as a potential future treatment option in CD30-expressing lymphomas.?
|05/18/2020 - 06:58||
Enhertu granted Breakthrough Therapy Designation in the US for HER2-mutant metastatic non-small cell lung cancer
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)?s Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a HER2 mutation and with disease progression on or after platinum-based therapy.
|05/18/2020 - 02:40||
ENHERTU Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Tokyo, Basking Ridge, NJ and Munich - (May 18, 2020) ? Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca?s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the U.S. for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a HER2 mutation and with disease progression on or after platinum-based therapy.
|05/17/2020 - 20:39||
WuXi Advanced Therapies Launches New Closed Process CAR-T Cell Therapy Platform
World-class platform will enable biotechnology companies and researchers to accelerate the development, manufacturing and release of cell and gene therapies for patients
|05/15/2020 - 17:04||
FDA Approves First Drug for Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumors
Today, the U.S. Food and Drug Administration approved Qinlock (ripretinib) tablets as the first new drug specifically approved as a fourth-line treatment for advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract. Qinlock is indicated for adult patients who have received prior treatment with three or more kinase inhibitor therapies, including imatinib.
|05/14/2020 - 06:34||
Positive Survival Data from Phase 2 Lung Cancer Trial Accepted for Presentation at 2020 American Society of Clinical Oncology (ASCO) Annual Meeting
Median overall survival (OS) of 28.7 months for HS-110 in combination with nivolumab in previously treated checkpoint inhibitor naïve non-small cell lung cancer (NSCLC) patients.
|05/14/2020 - 06:30||
OncoSec Partners with the Melanoma Research Foundation to Host Live Panel Discussion during Melanoma Awareness Month
OncoSec launches broader #TogetherAgainstCancer campaign and is proud to partner with melanoma advocacy partners throughout the month of May
|05/14/2020 - 00:03||
National Institutes of Health supports new research that could lead to personalized cancer treatments
Cytokine Release Syndrome is an overwhelming systemic immune response often seen in patients suffering from COVID-19. While this inflammatory response to germs, often called a “cytokine storm” can prove fatal, it also demonstrates the power of these small proteins secreted by lymphocytes to direct the body’s immune response to specific cells.